姚瓔珈,孔 亮,教亞男,李少恒,陶震宇,閆宇輝,楊靜嫻
(遼寧中醫(yī)藥大學(xué)藥學(xué)院藥理學(xué)教研室,遼寧大連 116600)
蛇床子素通過(guò)Wnt/β-catenin信號(hào)通路促進(jìn)轉(zhuǎn)染APP基因的神經(jīng)干細(xì)胞分化為更多神經(jīng)元且減少神經(jīng)元凋亡
姚瓔珈,孔 亮,教亞男,李少恒,陶震宇,閆宇輝,楊靜嫻
(遼寧中醫(yī)藥大學(xué)藥學(xué)院藥理學(xué)教研室,遼寧大連 116600)
中國(guó)圖書(shū)分類號(hào):R284.1;R322.8;R329.25;R341;R394.2;R745.702.6
摘要:目的 通過(guò)轉(zhuǎn)染APP基因于神經(jīng)干細(xì)胞,研究蛇床子素對(duì)其增殖和分化能力的影響,及對(duì)神經(jīng)元凋亡的影響,并研究其機(jī)制。方法 體外建立阿爾茨海默病的神經(jīng)干細(xì)胞模型,利用免疫組化染色法,研究蛇床子素對(duì)轉(zhuǎn)染APP基因的神經(jīng)干細(xì)胞增殖和分化能力的影響;通過(guò)CCK-8法檢測(cè)神經(jīng)干細(xì)胞存活率;Hoechst 33258法檢測(cè)神經(jīng)元凋亡情況;RT-PCR法檢測(cè)GSK-3β和β-catenin mRNA的表達(dá)變化情況;Western blot法檢測(cè)GSK-3β和β-catenin蛋白的表達(dá)變化情況。結(jié)果 與APP組相比,蛇床子素組的神經(jīng)干細(xì)胞增殖能力提高了10.24%;分化為神經(jīng)元的能力提高了6.74%。與APP組相比,蛇床子素組神經(jīng)干細(xì)胞的存活率明顯提高;神經(jīng)元凋亡明顯減少;RT-PCR和Western blot結(jié)果顯示,蛇床子素可抑制GSK-3β基因和蛋白的表達(dá),促進(jìn)β-catenin基因和蛋白的表達(dá)。結(jié)論 蛇床子素可促進(jìn)轉(zhuǎn)染APP基因的神經(jīng)干細(xì)胞的增殖,可促進(jìn)其分化為更多的神經(jīng)元,并減少神經(jīng)元凋亡,可能與通過(guò)激活Wnt/β-catenin信號(hào)通路有關(guān)系。
關(guān)鍵詞:阿爾茨海默??;神經(jīng)干細(xì)胞;增殖;分化;神經(jīng)元;蛇床子素;Wnt/β-catenin信號(hào)通路
網(wǎng)絡(luò)出版時(shí)間:2015-10-16 9:52 網(wǎng)絡(luò)出版地址:http://www.cnki.net/kcms/detail/34.1086.R.20151016.0952.018.html
阿爾茨海默病(Alzheimer′s disease,AD)是最常見(jiàn)的一種與年齡有關(guān)的癡呆病,AD主要的病理特征是β淀粉樣蛋白(Aβ)的沉積,神經(jīng)元纖維的纏結(jié)(NFTs)和大量神經(jīng)元的丟失[1]。AD的病理特征為認(rèn)知功能退行性病變和記憶、學(xué)習(xí)能力的下降,且中老年人群中發(fā)病率較高[2-3]。神經(jīng)再生是一個(gè)由神經(jīng)干細(xì)胞產(chǎn)生新的神經(jīng)元的過(guò)程[4],保持著神經(jīng)干細(xì)胞的增殖、遷移和分化為神經(jīng)元功能之間的平衡,很多神經(jīng)退行性疾病正是因?yàn)榇斯δ芟陆祵?dǎo)致的。那么,提高大腦內(nèi)內(nèi)源性神經(jīng)干細(xì)胞的存活和增殖能力,補(bǔ)充丟失的神經(jīng)元,將是一個(gè)非常有潛力的治療途徑。我們之前的研究已經(jīng)證明了蛇床子素(osthole,Ost)對(duì)正常狀態(tài)下的神經(jīng)干細(xì)胞的增殖和分化的影響,可減少Aβ孵育的神經(jīng)細(xì)胞中Aβ蛋白的表達(dá)[5],這為后續(xù)實(shí)驗(yàn)提供了實(shí)驗(yàn)依據(jù)??扇苄訟β寡聚體的沉積和神經(jīng)元的丟失是導(dǎo)致AD認(rèn)知功能障礙的主要致病因素[6]?,F(xiàn)有大量文獻(xiàn)證明,與AD發(fā)生有關(guān)的這些有毒性的Aβ是由Aβ前體樣蛋白(APP蛋白)通過(guò)β-分泌酶和γ-分泌酶水解而產(chǎn)生的[7]。體內(nèi)還存在與APP蛋白結(jié)構(gòu)相似的APLP1[8]和APLP2[9]蛋白。大量的文獻(xiàn)表明,AD的發(fā)生是與Wnt/β-catenin信號(hào)通路介導(dǎo)的Aβ產(chǎn)生神經(jīng)毒性有關(guān)[10]。
Wnt/β-catenin信號(hào)通路參與了細(xì)胞的增殖、分化、神經(jīng)元凋亡等,且在AD的發(fā)生和發(fā)展中發(fā)揮著重要作用。Wnt信號(hào)通路存在兩種途徑:一種是經(jīng)典Wnt途徑,另一種是非經(jīng)典Wnt/PCP或者Wnt/Ca2+途徑[11]。GSK-3β是一種高度保守的絲氨酸/蘇氨酸激酶,也是Wnt/β-catenin信號(hào)通路上重要的媒介,它對(duì)細(xì)胞蛋白的合成、增殖、分化和凋亡等均有影響。Toledo等[12]已經(jīng)通過(guò)體內(nèi)實(shí)驗(yàn)發(fā)現(xiàn),氯化鋰作為GSK-3β的抑制劑,激活Wnt信號(hào)通路,上調(diào)β-catenin表達(dá)水平,同時(shí)減輕AD模型APPswe/PSEN1ΔE9雙轉(zhuǎn)基因小鼠的空間記憶障礙,減少Aβ聚集。Balaraman等[13]發(fā)現(xiàn)在AD患者腦內(nèi),Wnt/β-catenin通路活性處于抑制狀態(tài),導(dǎo)致GSK-3β表現(xiàn)出高活性。β-catenin為該信號(hào)通路上一個(gè)關(guān)鍵點(diǎn),它是GSK-3β下游靶點(diǎn),在AD中明顯下降。它的丟失將破壞增殖、生長(zhǎng),引起神經(jīng)元的死亡[14]。β-catenin代表著經(jīng)典Wnt/β-catenin信號(hào)通路,對(duì)神經(jīng)發(fā)生和發(fā)展有重要的作用[15]。因此,通過(guò)刺激內(nèi)源性神經(jīng)干細(xì)胞的再生和增殖將是治療AD的一種有效的治療途徑。
蛇床子素(7-甲氧基-8-異戊烯基香豆素,ost-
hole,Ost)化學(xué)式:C15H16O3,分子質(zhì)量:244.38 u,是一種從多種中藥如蛇床子(Angelica pubescens Maxim.f.biserrata Shan et Yuan)中提取的天然香豆素,現(xiàn)如今確定的藥理作用包括抗炎、調(diào)節(jié)免疫作用等[16-17]。我們之前的研究已經(jīng)證明,Ost能夠減輕神經(jīng)細(xì)胞由Aβ產(chǎn)生的神經(jīng)毒性[4],又可提高以神經(jīng)干細(xì)胞為基礎(chǔ)實(shí)驗(yàn)性的自身免疫性腦脊髓炎的治療效率[18]。
在之前的研究中,我們發(fā)現(xiàn)Ost對(duì)正常狀態(tài)下的神經(jīng)干細(xì)胞具有促進(jìn)其增殖和分化的作用,但是,Ost對(duì)由APP轉(zhuǎn)染產(chǎn)生Aβ的神經(jīng)干細(xì)胞增殖、分化和遷移能力的報(bào)道卻少見(jiàn)。因此,我們想通過(guò)實(shí)驗(yàn)證明Ost可提高轉(zhuǎn)染APP基因的神經(jīng)干細(xì)胞的增殖和存活能力,并促進(jìn)其分化為神經(jīng)元,減少神經(jīng)元凋亡,這將為Ost預(yù)防和治療AD提供新的理論依據(jù)。
1.1材料
1.1.1試劑 Ost(批號(hào):110822-200305,純度>98%,244.39分子質(zhì)量;結(jié)構(gòu)見(jiàn)Fig 1)購(gòu)自于中國(guó)藥品檢驗(yàn)所(北京,中國(guó));DMEM/F12培養(yǎng)基、胎牛血清(FBS)、雙抗(100 kU·L-1青霉素+100 mg·L-1鏈霉素)(美國(guó)Gibco公司);堿性成纖維細(xì)胞生長(zhǎng)因子(basic fibroblast growth factor,bFGF)、表皮生長(zhǎng)因子(epidermal growth factor,EGF)(美國(guó)Peptide公司);B27添加劑(B27)(美國(guó)Invitrogen公司);DM-SO(美國(guó)Sigma公司);LiCl(上海生工生物公司);IWR-1-endo(美國(guó)Selleck公司);CCK-8試劑盒(美國(guó)Dojindo公司);大鼠抗巢蛋白(Nestin)抗體、兔抗干細(xì)胞關(guān)鍵蛋白(SOX2)抗體(美國(guó)Millipore公司);Cy3標(biāo)記驢抗兔IgG抗體(美國(guó)Jackson公司);兔抗Ki67抗體、兔抗膠質(zhì)纖維酸性蛋白(GFAP)抗體、兔抗少突膠質(zhì)細(xì)胞前體蛋白(NG2)抗體、兔抗神經(jīng)元核(NeuN)抗體(北京博奧森公司);Hoechst 33258試劑(北京碧云天公司);第一鏈cDNA合成(RevertAidTMFirst Strand cDNA Synthesis Kit)試劑盒和PCR引物擴(kuò)增(PCR Master Mix Kit)試劑盒(美國(guó)Thermo公司);全蛋白提取試劑盒、Braford法檢測(cè)蛋白濃度試劑盒、蛋白緩沖液上樣試劑盒(南京凱基生物科技發(fā)展有限公司)。
Fig 1 Chemical structure of osthole
1.1.2動(dòng)物 自然分娩48 h內(nèi)的小鼠(SPF級(jí)昆明種小鼠),體質(zhì)量2~3 g,購(gòu)自大連醫(yī)科大學(xué)實(shí)驗(yàn)動(dòng)物中心,動(dòng)物許可證編號(hào):SCXK(遼)2008-0002。
1.1.3儀器 倒置熒光生物顯微鏡(日本尼康公司);超低溫冰箱(青島海爾股份有限公司);CO2培養(yǎng)箱(型號(hào):NU-4750E,美國(guó)Nuaire公司);紫外-可見(jiàn)光分光光度計(jì)(型號(hào):UV-5600,深圳邁瑞生物醫(yī)療電子股份有限公司);酶標(biāo)儀(型號(hào):MR-96A,深圳邁瑞生物醫(yī)療電子股份有限公司);PCR儀(型號(hào):MG96G,杭州朗基科學(xué)儀器有限公司);凝膠成像儀(型號(hào):4100,上海天能科技有限公司);水平核酸電泳儀(型號(hào):PowerPac系列,美國(guó)Bio-Rad公司)。
1.2方法
1.2.1實(shí)驗(yàn)分組 將細(xì)胞隨機(jī)分為7組,每組3個(gè)復(fù)孔,重復(fù)3次。分別為:①GFP組;②APP組;③Ost組;④LiCl組;⑤APP+LiCl組;⑥IWR-1-endo組;⑦IWR-1-endo+Ost組。
1.2.2蛇床子素的配制 Ost溶解于二甲基亞砜(DMSO)中,DMSO濃度最大比例不超過(guò)0.1%。用磷酸鹽緩沖鹽水(PBS)液稀釋成濃度為1 nmol· L-1Ost母液,并在-20℃儲(chǔ)存?zhèn)溆茫?9]。本實(shí)驗(yàn)中APP組細(xì)胞經(jīng)過(guò)DMSO溶劑處理,且DMSO體積與給藥組的DMSO體積相等,即APP組為溶劑(DM-SO)對(duì)照組。
1.2.3神經(jīng)干細(xì)胞的培養(yǎng) 取新生2 d內(nèi)乳鼠的腦室下區(qū)(SVZ)和海馬區(qū)(hippocampus)[20],然后將神經(jīng)干細(xì)胞培養(yǎng)在完全培養(yǎng)基內(nèi),完全培養(yǎng)基包括1%B 27、20 μg·L-1bFGF、20 μg·L-1EGF和100 kU·L-1的雙抗。分離純化的神經(jīng)干細(xì)胞以1 ×109個(gè)·L-1的密度接種于24孔板,放在37℃、5%CO2和95%空氣的培養(yǎng)箱內(nèi)開(kāi)始培養(yǎng)[21]。在3 d后半量換液,然后細(xì)胞開(kāi)始慢慢地懸浮成長(zhǎng)為神經(jīng)干細(xì)胞。
1.2.4APP基因轉(zhuǎn)染 第3代的神經(jīng)干細(xì)胞用于后續(xù)實(shí)驗(yàn),我們的實(shí)驗(yàn)要通過(guò)慢病毒轉(zhuǎn)染1個(gè)與AD致病因素有關(guān)的APP質(zhì)粒[22],此方法已經(jīng)成功用于IL-10轉(zhuǎn)染神經(jīng)干細(xì)胞[23]和CCR5轉(zhuǎn)染骨髓源神經(jīng)干細(xì)胞[24]。先將GFP和APP質(zhì)粒用試劑脂質(zhì)體2000來(lái)包裝293T細(xì)胞,在24 h后,熒光顯微鏡下觀察熒光情況。在36、72 h后收集上清病毒液,并將神經(jīng)干細(xì)胞打散為單個(gè)細(xì)胞,用于轉(zhuǎn)染GFP和APP基因,在轉(zhuǎn)染3 d后,熒光顯微鏡下觀察轉(zhuǎn)染情況。
1.2.5熒光免疫組化染色和Hoechst 33258染色96孔板培養(yǎng)的神經(jīng)干細(xì)胞在4℃,用4%多聚甲醛
固定30 min,然后用PBS液清洗,再用1%Triton室溫透化30min[25]。然后選擇相應(yīng)的一抗抗體:小鼠抗巢蛋白、兔抗星形膠質(zhì)細(xì)胞、兔抗少突膠質(zhì)細(xì)胞、小鼠抗神經(jīng)元和兔抗Ki67,用1%BSA溶解后4℃孵育過(guò)夜,次晨用相對(duì)應(yīng)的二抗孵育1 h后,用PBS液清洗3次。細(xì)胞核用4′6-二脒基-2-苯基吲哚(DAPI)染色15 min。用免疫熒光顯微鏡計(jì)數(shù)每孔免疫熒光陽(yáng)性細(xì)胞。分化24 h后的細(xì)胞再用PBS液溶解Hoechst 33258染料,孵育30 min[26],凋亡的細(xì)胞會(huì)出現(xiàn)細(xì)胞核內(nèi)的顆粒塊熒光[27],從而確定凋亡細(xì)胞百分比,每孔實(shí)驗(yàn)重復(fù)3次。
1.2.6CCK-8法檢測(cè)細(xì)胞存活率 神經(jīng)干細(xì)胞的存活率通過(guò)CCK-8試劑盒檢測(cè)[28],打散的單個(gè)神經(jīng)干細(xì)胞以每孔5×107個(gè)·L-1細(xì)胞密度接種于96孔板,每組重復(fù)3孔。不同組別在培養(yǎng)箱內(nèi)孵育48 h后,每孔加入10 μL的CCK-8試劑,再培養(yǎng)4 h。在450 nm波長(zhǎng)處,用酶標(biāo)儀檢測(cè)吸光度,該吸光度的數(shù)值大小與神經(jīng)干細(xì)胞存活的數(shù)量密切相關(guān)。
1.2.7RT-PCR檢測(cè)相關(guān)基因的表達(dá)情況 提取轉(zhuǎn)染了APP和GFP基因神經(jīng)干細(xì)胞的總RNA,根據(jù)說(shuō)明書(shū),加入1 mL TRIzol試劑,然后用第一鏈cDNA合成試劑盒逆轉(zhuǎn)錄成cDNA。我們所用引物純度幾乎接近100%,所用引物序列為:APP-F(5′-GACTGACCACTCGACCAGCAGGTTCTG-3′),APP-R (5′-CTTGTAAGTTGGATTCTCATATCCG-3′);GSK-3β-F(5′-CAACAGCCACCCCAAGAC-3′),GSK-3β-R (5′-GATCCCATCTGGTCATCC-3′);β-catenin-F(5′-CCACTCCAGGAATGAAGG-3′),β-catenin-R(5′-AG-CAGTCTCATTCCAAGC-3′);β-actin-F(5′-GG-GAAATCGTGCGTGACAT-3′),β-actin-R(5′-TCAG-GAGGAGCAATGATCTTG-3′)。使用PCR試劑盒進(jìn)行35個(gè)循環(huán)的PCR反應(yīng)[5]。用Image J圖像分析軟件對(duì)條帶進(jìn)行吸光度掃描,結(jié)果用相對(duì)光密度表示,相對(duì)光密度=光密度目的基因/光密度β-actin。
1.2.8免疫蛋白印跡法檢測(cè)相關(guān)蛋白的表達(dá)情況神經(jīng)干細(xì)胞用預(yù)冷的PBS液清洗,然后加入蛋白抑制劑,根據(jù)總蛋白提取試劑盒的說(shuō)明書(shū)提取總蛋白,然后通過(guò)Braford方法檢測(cè)總蛋白濃度[29]。每孔加入100 μg蛋白,用8%烷基硫酸鈉-聚丙烯酰胺凝膠(SDS-PAGE)轉(zhuǎn)移到聚偏二氟乙烯膜(PVDF)上[30],用一抗抗體和適合的辣根酶標(biāo)記過(guò)的二抗抗體孵育,PVDF膜用二氨基聯(lián)苯胺(DAB)染色試劑盒染色。用Image J圖像分析軟件對(duì)條帶進(jìn)行吸光度掃描,結(jié)果表示蛋白表達(dá)量變化情況。
1.2.9統(tǒng)計(jì)學(xué)分析 統(tǒng)計(jì)數(shù)據(jù)分析使用的是SPSS 13.0軟件,數(shù)據(jù)以平均數(shù)±方差表示,對(duì)所得數(shù)據(jù)進(jìn)行單因素方差分析和t檢驗(yàn)。所有的實(shí)驗(yàn)數(shù)據(jù)都獨(dú)立重復(fù)至少3次。
2.1轉(zhuǎn)染神經(jīng)干細(xì)胞中APP和GFP的表達(dá) 我們從C57BL/6新生乳鼠的SVZ和海馬區(qū)分離提取神經(jīng)干細(xì)胞,在大約d 7,神經(jīng)干細(xì)胞增殖為半徑更大的神經(jīng)球。第3代典型的神經(jīng)球用免疫組化染色法染色,共同表達(dá)神經(jīng)干細(xì)胞特異性標(biāo)志物Nestin(綠色)和Sox2(紅色),見(jiàn)Fig 2A。然后用APP和GFP慢病毒轉(zhuǎn)染神經(jīng)干細(xì)胞,質(zhì)粒結(jié)構(gòu)圖如Fig 2B。神經(jīng)干細(xì)胞轉(zhuǎn)染APP基因的轉(zhuǎn)染率大概為85% (Fig 2C),大量表達(dá)APP基因和APP蛋白,見(jiàn)Fig 2D和2E。
2.2蛇床子素可促進(jìn)轉(zhuǎn)染APP基因的神經(jīng)干細(xì)胞增殖 Ost具有明顯的促進(jìn)神經(jīng)球形成的作用(Fig 3A)。我們將第5代神經(jīng)干細(xì)胞在d 1、4、8、12、15采用機(jī)械法將其打散為單個(gè)細(xì)胞,并在增殖培養(yǎng)基內(nèi)培養(yǎng),通過(guò)對(duì)單個(gè)細(xì)胞的計(jì)數(shù),繪制生長(zhǎng)曲線圖[19]。Fig 3B生長(zhǎng)曲線顯示Ost促進(jìn)轉(zhuǎn)染APP基因的神經(jīng)干細(xì)胞數(shù)目的增多。在d 7,用Ki67染色法檢測(cè)其增殖能力[31],見(jiàn)Fig 3C。結(jié)果發(fā)現(xiàn),與正常組相比,APP組Ki67陽(yáng)性率明顯下降了24.80% (P<0.01);給藥組Ki67陽(yáng)性率比APP組明顯增強(qiáng)了10.24%(P<0.05),見(jiàn)Fig 3D。
2.3蛇床子素可促進(jìn)轉(zhuǎn)染APP基因的神經(jīng)干細(xì)胞分化為更多的神經(jīng)元 為了證明Ost(100 μmol· L-1)對(duì)體外轉(zhuǎn)染APP質(zhì)粒的神經(jīng)干細(xì)胞分化能力的影響,我們將打散后的單個(gè)細(xì)胞放在分化培養(yǎng)基內(nèi)培養(yǎng)。大約在12d后,通過(guò)免疫組化法檢測(cè)神經(jīng)干細(xì)胞分化為星形膠質(zhì)細(xì)胞(GFAP+)、神經(jīng)元(Ne-uN+)和少突膠質(zhì)細(xì)胞(NG2+)的情況[32],見(jiàn)Fig 4A。根據(jù)定量分析后可得(Fig 4B),Ost作用后神經(jīng)干細(xì)胞分化為更少的星形膠質(zhì)細(xì)胞(APP組vs Ost組:62.67%±2.05%vs 54.27%±1.79%,P<0.01)和更多的神經(jīng)元(APP組vs Ost組:19.53% ±2.25%vs 26.27%±3.19%,P<0.05),但是對(duì)少突膠質(zhì)細(xì)胞無(wú)明顯影響(APP組vs Ost組:29.9%± 2.85%vs 28.2%±1.68%)。
Fig 2 Transduction of NSCs for APP and GFP expression
Fig 3 Osthole promotes APP transduced NSCs proliferation in vitro
2.4蛇床子素通過(guò)Wnt/β-catenin通路提高神經(jīng)干細(xì)胞存活率并且減少神經(jīng)元凋亡 為了驗(yàn)證Ost是否通過(guò)Wnt/β-catenin信號(hào)通路來(lái)提高神經(jīng)干細(xì)胞的存活率,我們?cè)趯?shí)驗(yàn)中用Wnt通路的抑制劑來(lái)阻斷通路信號(hào)和Wnt通路的激動(dòng)劑來(lái)激活信號(hào)。神經(jīng)干細(xì)胞用Ost(100 μmol·L-1)、IWR-1-endo
(Wnt信號(hào)通路抑制劑,10 μmol·L-1)和LiCl(20 mmol·L-1)作用后[33],我們采用免疫熒光染色法檢測(cè),繪制出凋亡細(xì)胞百分比,見(jiàn)Fig 5A和5B,結(jié)果顯示Ost作用后,降低了神經(jīng)元的凋亡。然后,再將細(xì)胞重新接種后的d 3采用CCK-8試劑孵育4 h,檢測(cè)細(xì)胞存活率。正如Fig 5C所示,LiCl組、Ost組、LiCl+Ost組的細(xì)胞存活率與APP組相比有明顯升高(85.76%±4.02%、77.30%±3.41%、94.02%± 4.12%vs 69.03%±3.98%,P<0.05,P<0.01),IWR-1-endo組、IWR-1-endo+Ost組的存活率與APP組相比有明顯下降(53.03%±3.19%、54.25% ±4.03%vs 69.03%±3.98%,P<0.05),但是IWR-1-endo組和IWR-1-endo+Ost組之間的細(xì)胞存活率差異無(wú)顯著性。
Fig 4 Osthole promotes differentiation into greater number of neurons
Fig 5 Osthole promotes the survival of transfected NSCs and reduces neuronal apoptosis
Fig 6 Effects of various treatment on the expression of GSK-3β,β-catenin mRNA and protein
2.5蛇床子素激活Wnt信號(hào)通路并抑制GSK-3β活性 Fig 6結(jié)果顯示,Ost能夠降低轉(zhuǎn)染APP質(zhì)粒的神經(jīng)干細(xì)胞中GSK-3β的mRNA表達(dá),使β-cate-nin的mRNA表達(dá)升高。正如這樣的情況,LiCl作用后,β-catenin蛋白增多。當(dāng)用抑制劑IWR-1-endo作用后,GSK-3β mRNA及GSK-3β蛋白表達(dá)升高,但是與給藥組之間相比無(wú)明顯變化。
AD是一種神經(jīng)退行性疾病,在工業(yè)大國(guó)約有2%的人口會(huì)得此病,并且這個(gè)數(shù)目在50年內(nèi)會(huì)翻兩倍[34]。通過(guò)查閱文獻(xiàn),我們知道與AD有關(guān)的Aβ是由APP蛋白水解產(chǎn)生的,而這些有毒性的Aβ寡聚體沉積與AD病人的認(rèn)知功能下降有密切關(guān)系[35]。Ost是一種天然香豆素類化合物,因?yàn)榫哂胁煌乃幚碜饔?,被認(rèn)為具有強(qiáng)大的治療潛能[36]。根據(jù)已知的Ost的藥理作用,例如抗炎[17]、抗氧化[37]和神經(jīng)保護(hù)作用[38],還有我們之前實(shí)驗(yàn)研究發(fā)現(xiàn),Ost可促進(jìn)正常狀態(tài)下的神經(jīng)干細(xì)胞的增殖和分化,那么,我們通過(guò)成功構(gòu)建一種模擬AD病理特點(diǎn)的體外AD細(xì)胞模型,來(lái)研究Ost對(duì)轉(zhuǎn)染APP的神經(jīng)干細(xì)胞的增殖和分化能力的影響。
通過(guò)實(shí)驗(yàn),我們發(fā)現(xiàn)由APP產(chǎn)生的Aβ寡聚體會(huì)抑制神經(jīng)干細(xì)胞的增殖和分化。通過(guò)Ki67染色法發(fā)現(xiàn),與APP組相比,Ost組的增殖能力明顯提高,并分化為更多神經(jīng)元,但兩組比較,分化為少突膠質(zhì)細(xì)胞的能力差異無(wú)顯著性。
為了探索Ost的作用機(jī)制,我們選取了Wnt/β-catenin信號(hào)通路上的激動(dòng)劑和抑制劑。利用NeuN 和Hoechst 33258染色,神經(jīng)元凋亡數(shù)目的結(jié)果說(shuō)明Ost具有抗神經(jīng)元凋亡的作用。再用CCK-8試劑盒檢測(cè)神經(jīng)干細(xì)胞的存活率,我們的結(jié)果顯示,Ost可促進(jìn)神經(jīng)干細(xì)胞的存活率,但I(xiàn)WR-1-endo組和IWR-1-endo+Ost組之間的細(xì)胞存活率差異無(wú)顯著性。為了進(jìn)一步了解Ost抗神經(jīng)元凋亡的分子機(jī)制,我們隨后利用RT-PCR技術(shù)檢測(cè)了Wnt/β-cate-nin信號(hào)通路上的基因。本實(shí)驗(yàn)的結(jié)果表明,在LiCl 或Ost作用后,GSK-3β的mRNA表達(dá)下降,而β-catenin的mRNA表達(dá)上升。我們又用Western blot技術(shù)檢測(cè)了GSK-3β、β-catenin蛋白表達(dá),Western blot結(jié)果與RT-PCR結(jié)果是一致的。以上結(jié)果說(shuō)明
Ost是通過(guò)激活Wnt/β-catenin信號(hào)通路,抑制GSK-3β活性,并激活β-catenin活性,在體外發(fā)揮減少神經(jīng)元凋亡的作用。
一直以來(lái),AD的發(fā)病機(jī)制尚未清楚,所以對(duì)神經(jīng)干細(xì)胞用于AD潛在治療的研究已經(jīng)遠(yuǎn)遠(yuǎn)落后于其他神經(jīng)退行性疾病。為了發(fā)現(xiàn)Ost是通過(guò)激活Wnt/β-catenin信號(hào)通路,促進(jìn)神經(jīng)干細(xì)胞的增殖和存活能力,提高向神經(jīng)元的分化能力,并且減少神經(jīng)元的凋亡,我們使用了Wnt/β-catenin信號(hào)通路的激動(dòng)劑和抑制劑,證明了Ost發(fā)揮藥理作用是與此通路有關(guān)。從所有結(jié)果來(lái)看,Ost將會(huì)是一種非常具有潛能用于治療AD或者其他神經(jīng)退行性疾病的藥物。
參考文獻(xiàn):
[1] Castellani R J,Lee H G,Zhu X,et al.Alzheimer disease pathol-ogy as a host response[J].J Neuropathol Exp Neurol,2008,67 (6):523-31.
[2] Castellani R J,Rolston R K,Smith M A.Alzheimer disease[J].Dis Mon,2010,56(9):484-546.
[3] 張 喻,肇玉明,王曉良,彭 英.干細(xì)胞治療阿爾茨海默病的研究進(jìn)展及挑戰(zhàn)[J].中國(guó)藥理學(xué)通報(bào),2015,31(7):889-94.
[3] Zhang Y,Zhao Y M,Wang X L,Peng Y.Advance and challen-ges in stem cell therapy for Alzheimer's disease[J].Chin Pharma-col Bull,2015,31(7):889-94.
[4] Zhao C,Deng W,Gage F H.Mechanisms and functional implica-tions of adult neurogenesis[J].Cell,2008,132(4):645-60.
[5] Hu Y,Wen Q,Liang W,et al.Osthole reverses beta-amyloid peptide cytotoxicity on neural cells by enhancing cyclic AMP re-sponse element-binding protein phosphorylation[J].Biol Pharm Bull,2013,36(12):1950-8.
[6] Lee I S,Jung K,Kim I S,Park K I.Amyloid-β oligomers regu-late the properties of human neural stem cells through GSK-3β sig-naling[J].Exp Mol Med,2013,45:e60.
[7] Kayed R,Head E,Thompson J L,et al.Common structure of sol-uble amyloid oligomers implies common mechanism of pathogenesis [J].Science,2003,300(5618):486-9.
[8] Wasco W,Bupp K,Magendantz M,et al.Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor[J].Proc Natl Acad Sci USA,1992,89(22):10758-62.
[9] Wasco W,Gurubhagavatula S,Paradis M D,et al.Isolation and characterization of APLP2 encoding a homologue of the Alzheimer′s associated amyloid beta protein precursor[J].Nat Genet,1993,5(1):95-100.
[10]Inestrosa N C,Toledo E M.The role of Wnt signaling in neuronal dysfunction in Alzheimer′s Disease[J].Mol Neurodegener,2008,3:9.
[11]Gordon M D,Nusse R.Wnt signaling:multiple pathways,multi-ple receptors,and multiple transcription factors[J].J Biol Chem,2006,281(32):22429-33.
[12]Toledo E M,Inestrosa N C.Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurode-generationin brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer′s disease[J].Mol Psychiatry,2010,15(3):272-85,228.
[13]Balaraman Y,Limaye A R,Levey A I,Srinivasan S.Glycogen synthase kinase 3beta and Alzheimer's disease:pathophysiological and therapeutic significance[J].Cell Mol Life Sci,2006,63 (11):1226-35.
[14]Zhang Q G,Wang R,Khan M,et al.Role of Dickkopf-1,an an-tagonist of the Wnt/beta-catenin signaling pathway,in estrogen-in-duced neuroprotection and attenuation of tau phosphorylation[J].J Neurosci,2008,28(34):8430-41.
[15]Lie D C.Wnt signalling regulates adult hippocampal neurogenesis [J].Nature,2005,437(7063):1370-5.
[16]Chen T,Liu W,Chao X,et al.Neuroprotective effect of osthole against oxygen and glucose deprivation in rat cortical neurons:in-volvement of mitogen-activated protein kinase pathway[J].Neuro-science,2011,183:203-11.
[17]Ji H J,Hu J F,Wang Y H,et al.Osthole improves chronic cere-bral hypoperfusion induced cognitive deficits and neuronal damage in hippocampus[J].Eur J Pharmacol,2010,636(1-3):96-101.
[18]Gao Z,Wen Q,Xia Y,et al.Osthole augments therapeutic effi-ciency of neural stem cells-based therapy in experimental autoim-mune encephalomyelitis[J].J Pharmacol Sci,2014,124(1):54 -65.
[19]Zhang N,Kang T,Xia Y,et al.Effects of salvianolic acid B on survival,self-renewal and neuronal differentiation of bone marrow derived neural stem cells[J].Eur J Pharmacol,2012,697(1-3):32-9.
[20]Van Praag H,Schinder A F,Christie B R,et al.Functional neu-rogenesis in the adult hippocampus[J].Nature,2002,415 (6875):1030-4.
[21]成 薇,沈長(zhǎng)波,王 莉,等.白藜蘆醇預(yù)處理對(duì)氧糖剝奪/再?gòu)?fù)氧損傷大鼠皮質(zhì)神經(jīng)干細(xì)胞增殖的影響[J].中國(guó)藥理學(xué)通報(bào),2015,31(1):113-8.
[21]Cheng W,Shen C B,Wang L,et al.Effect of resveratrol pretreat-ment on proliferation of cortical neural stem cells after oxygenglucose deprivation/reoxygenation injury in rats[J].Chin Phar-macol Bull,2015,31(1):113-8.
[22]Escribano L,Simón A M,Gimeno E,et al.Rosiglitazone rescues memory impairment in Alzheimer′s transgenic mice:mechanisms involving a reduced amyloid and tau pathology[J].Neuropsycho-pharmacology,2010,35(7):1593-604.
[23]Yang J,Jiang Z,F(xiàn)itzgerald D C,et al.Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelina-tion in experimental autoimmune encephalitis[J].J Clin Invest,2009,119(12):3678-91.
[24]Yang J,Yan Y,Ma C G,et al.Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis[J].Acta Neuropathol,2012,124(4):491-503.
[25]Hamamoto R,F(xiàn)urukawa Y,Morita M,et al.SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells[J].Nat Cell Biol,2004,6(8):731-40.
[26]Zhang N,Wen Q,Ren L,et al.Neuroprotective effect of arctige-nin via upregulation of P-CREB in mouse primary neurons and hu-man SH-SY5Y neuroblastoma cells[J].Int J Mol Sci,2013,14 (9):18657-69.
[27]Fang M,Wang J,Zhang X,et al.The miR-124 regulates the ex-pression of BACE1/β-secretase correlated with cell death in Alzhe-imer′s disease[J].Toxicol Lett,2012,209(1):94-105.
[28]Yang J,Bridges K,Chen K Y,Liu A Y.Riluzole increases the a-mount for latent HSF1 for an amplified heat shock response and cy-toprotection[J].PLoS One,2008,3(8):e2864.
[29]Trazzi S,Mitrugno V M,Valli E,et al.APP-dependent up-regu-lation of Ptch1 underlies proliferation impairment of neural precur-sors in Down syndrome[J].Hum Mol Genet,2011,20(8):1560 -73.
[30]Itokazu Y,Yu R K.Amyloid β-peptide 1-42 modulates the prolif-eration of mouse neural stem cells:upregulation of fucosyltrans-ferase IX and notch signaling[J].Mol Neurobiol,2014,50(1):186-96.
[31]Schonk D M,Kuijpers H J,van Drunen E,et al.Assignment of the gene(s)involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10[J].Hum Genet,1989,83(3):297-9.
[32]Yang J,Yan Y,Xia Y,et al.Neurotrophin 3 transduction aug-ments remyelinating and immunomodulatory capacity of neural stem cells[J].Mol Ther,2014,22(2):440-50.
[33]Chen B,Dodge M E,Tang W,et al.Small molecule-mediated dis-ruption of Wnt-dependent signaling in tissue regeneration and cancer[J].Nat Chem Biol,2009,5(2):100-7.
[34]Mattson M P.Pathways towards and away from Alzheimer′s disease [J].Nature,2004,430(7000):631-9.
[35]Kim S U,Lee H J,Kim Y B.Neural stem cell-based treatment for neurodegenerative diseases[J].Neuropathology,2013,33(5):491-504.
[36]Ji H J,Hu J F,Wang Y H,et al.Osthole improves chronic cere-bral hypoperfusion induced cognitive deficits and neuronal damage in hippocampus[J].Eur J Pharmacol,2010,636(1-3):96-101.
[37]Hua K F,Yang S M,Kao T Y,et al.Osthole mitigates progres-sive IgA nephropathy by inhibiting reactive oxygen species genera-tion and NF-κB/NLRP3 pathway[J].PLoS One,2013,8(10):e77794.
[38]Chao X,Zhou J,Chen T,et al.Neuroprotective effect of osthole against acute ischemic stroke on middle cerebral ischemia occlu-sion in rats[J].Brain Res,2010,1363:206-11.
Osthole promotes differentiation into neurons and reduces neuronal apoptosis via Wnt/β-catenin signaling pathway in APP transduced neural stem cells
YAO Ying-jia,KONG Liang,JIAO Ya-nan,LI Shao-heng,TAO Zhen-yu,YAN Yu-hui,YANG Jing-xian
(Dept of Pharmacology,School of Pharmacy,Liaoning University of Traditional Chinese Medicine,Dalian Liaoning 116600,China)
Abstract:Aim To investigate the effects of osthole (Ost)on the ability of proliferation and differentiation in APP transduced neural stem cells(NSCs),and neu-ronal apoptosis,in order to find related mechanism.Methods A model of Alzheimer′s disease(AD)cells was successfully established by transducing APP gene into NSCs in vitro.The ability of proliferation and dif-ferentiation was tested by staining.The viability of NSCs was determined by using CCK-8 assay.The cell apoptosis was tested by Hoechst 33258 staining.The expression of GSK-3β and β-catenin mRNA was deter-mined by RT-PCR.The expression of GSK-3β and β-catenin protein was determined by Western blot.Re-sults The ability of proliferation had increased by 10.24%with Ost treatment,compared with APP group. The ability of differentiation had increased by 6.74% with Ost treatment,compared with APP group.The vi-ability of NSCs had increased and cell apoptotic rate had decreased significantly.From the results of RT-PCR and Western blot,we could find the expression of GSK-3β mRNA and protein had decreased,and the ex-pression of β-catenin mRNA and protein had increased significantly,compared with APP group.Conclusion Ost could enhance the ability of proliferation and dif-ferentiation into more neurons of NSCs transducing APP gene,and reduce neuronal apoptosis.It might be relat-ed with activiting Wnt/β-catenin signaling pathway.
Key words:Alzheimer′s disease;neural stem cells;proliferation;differentiation;neurons;osthole;Wnt/β-catenin signaling pathway
作者簡(jiǎn)介:姚瓔珈(1990-),女,碩士生,研究方向:神經(jīng)藥理學(xué),E-mail:yaoyj23@qq.com;楊靜嫻(1963-),女,博士,教授,博士生導(dǎo)師,研究方向:神經(jīng)藥理學(xué),通訊作者,Tel:0411-87586009,E-mail:jingx-ianyang@yahoo.com
基金項(xiàng)目:國(guó)家自然科學(xué)基金資助項(xiàng)目(No 81173580)
收稿日期:2015-06-11,修回日期:2015-07-20
文獻(xiàn)標(biāo)志碼:A
文章編號(hào):1001-1978(2015)11-1516-08
doi:10.3969/j.issn.1001-1978.2015.11.009
中國(guó)藥理學(xué)通報(bào)2015年11期